glp-1 receptor agonists in pediatric and adolescent obesity obesity: an integrative perspective on cell signaling, development, metabolism Role of GLP-1 Receptor Agonists
Description
ZP 6590 [64] ZP-6590 is a GIPR agonist, and has been designed to both reduce nausea and food intake
Eriodictyol stimulates insulin secretion through cAMP/PKA signaling pathway in mice islets
Liraglutide Liraglutide was approved in December 2020 for weight management in adolescents aged 12 and older with a body weight above 60 kg and an initial BMI corresponding to 30 kg/m or greater for adults
The Pasqua et al
GLP-1 medications work biologically to reset appetite and satiety, making the weight loss achievable and sustainable as long as the medication is continued
J Clin Endocrinol Metab (2020) 105:295063
